Literature DB >> 7237203

Studies in fentanyl-supplemented anaesthesia: awareness and effect of naloxone on early post-operative recovery.

J G Purdell-Lewis, D M Blair, C A McLeod.   

Abstract

Ninety-nine unselected patients were given a standardized general anaesthetic with fentanyl 1.5 microgram . kg-1 every 30 minutes and were randomly divided into three equal groups; Group I patients received naloxone 0.1 mg. Group II naloxone 0.2 mg and Group III naloxone 0.4 mg intravenously at the end of the operation and after the reversal of neuromuscular blockade. After naloxone the level of consciousness lightened and the response to stimulus increased: the changes were significant in all three groups and the actual changes were significantly greater in Groups II and III compared with Group I. In the Recovery Room there was no significant difference among the Groups for shivering, nausea, vomiting or pain. The incidence of operative awareness was one per cent and that of dreaming eight per cent and this was unrelated to naloxone dosage. Patient acceptance was high, seven patients not wanting this type of anaesthesia again due to (a) light premedication (inherent in the study design), two patients; (b) nausea and vomiting, four patients; and (c) slow awakening, one patient.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237203     DOI: 10.1007/bf03007292

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  14 in total

1.  [Clinical studies on the usefulness of naloxone after short lasting anaesthesias with narcotic analgesics (author's transl)].

Authors:  W Dick; P Milewski; E Knoche; E Traub
Journal:  Anaesthesist       Date:  1978-06       Impact factor: 1.041

2.  Awareness and dreaming during anaesthesia in a paediatric hospital.

Authors:  B D McKie; E A Thorp
Journal:  Anaesth Intensive Care       Date:  1973-08       Impact factor: 1.669

3.  Awareness during anaesthesia: a comparison of anaesthesia with nitrous oxide-oxygen and nitrous oxide-oxygen with innovar.

Authors:  R A Browne; D V Catton
Journal:  Can Anaesth Soc J       Date:  1973-11

4.  Awareness during general anaesthesia for bronchoscopy and laryngoscopy using the apnoeic oxygenation technique.

Authors:  A M Barr; R M Wong
Journal:  Br J Anaesth       Date:  1973-08       Impact factor: 9.166

5.  Circulatory pattern and duration of action of naloxone in dogs with and without opioid pretreatment.

Authors:  E Schweichel; D Schmidt; E Schneider; J B Brückner
Journal:  Acta Anaesthesiol Scand       Date:  1979-08       Impact factor: 2.105

6.  Awareness during general anaesthesia: preliminary observations.

Authors:  J W McIntyre
Journal:  Can Anaesth Soc J       Date:  1966-09

7.  Postanaesthetic use of naloxone hydrochloride after moderate doses of fentanyl.

Authors:  R Andersen; I Dobloug; S Refstad
Journal:  Acta Anaesthesiol Scand       Date:  1976       Impact factor: 2.105

8.  Hemodynamic responses to low doses of naloxone after narcotic-nitrous oxide anesthesia.

Authors:  J M Desmonts; G Bohm; E Couderc
Journal:  Anesthesiology       Date:  1978-07       Impact factor: 7.892

9.  Antagonism of fentanyl with naloxone during N2O+O2+ halothane anaesthesia.

Authors:  I Tigerstedt
Journal:  Acta Anaesthesiol Scand       Date:  1977       Impact factor: 2.105

10.  Studies on fentanyl-supplemented anaesthesia: effect on naloxone on the circulation and respiration.

Authors:  J G Purdell-Lewis
Journal:  Can Anaesth Soc J       Date:  1980-07
View more
  3 in total

1.  General anaesthesia for day care surgery patients.

Authors:  R B Forbes
Journal:  Can Anaesth Soc J       Date:  1983-09

2.  Response of lower esophageal contractility to changing concentrations of halothane or isoflurane: a multicenter study.

Authors:  G A Maccioli; D R Kuni; G Silvay; J M Evans; J M Calkins; J A Kaplan
Journal:  J Clin Monit       Date:  1988-10

Review 3.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.